Department of Paediatric Haematology and Oncology, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
Br J Cancer. 2011 Mar 1;104(5):746-9. doi: 10.1038/bjc.2011.16. Epub 2011 Feb 15.
As most children with acute lymphoblastic leukaemia (ALL) achieve long-term survival, minimising late effects of treatment is a priority. Acute lymphoblastic leukaemia survivors treated historically with protocols including cranial irradiation demonstrate increased weight gain.
We retrospectively studied all 134 patients treated on the MRC/UKALL97 protocol (without cranial irradiation as standard therapy) at a single centre, with 77 inclusions. Height-, weight- and body mass index (BMI) standard-deviation scores (SDS) were recorded at diagnosis and annually until 3 years out (YO) from end of treatment (EoT); changes across time were explored using a univariate model (significance P ≤ 0.001 to account for multiple comparisons).
Whole-group height SDS was lower from 1 year into treatment until 2 YO, whereas weight- and BMI-SDS remained higher until 3 YO. In females, height-SDS was lower until EoT, but higher weight- and BMI-SDS persisted until 3 YO. In males, height-SDS was lower at EoT and at 2 YO; differences in BMI-SDS had resolved by 2 YO. By WHO criteria, more patients were overweight or obese at 3 YO than at diagnosis (P=0.01).
Survivors of childhood ALL, particularly females, exhibit adverse changes in height-, weight- and BMI-SDS, which arise during treatment and persist into follow-up. Patients should be supported with appropriate dietary and lifestyle advice during ALL treatment and follow-up, which may minimise these changes and reduce associated long-term morbidity.
大多数急性淋巴细胞白血病(ALL)患儿都能长期生存,因此最大限度地减少治疗的晚期影响是当务之急。历史上采用包括颅照射方案治疗的 ALL 患儿,其体重增加明显。
我们回顾性研究了在一个中心接受 MRC/UKALL97 方案(标准治疗不包括颅照射)治疗的 134 例 ALL 患儿,其中 77 例符合纳入标准。在诊断时和治疗结束后 3 年(EoT)内,每年记录身高、体重和体重指数(BMI)标准偏差评分(SDS);使用单变量模型探索随时间的变化(为了进行多次比较,显著性 P ≤ 0.001)。
全组身高 SDS 在治疗开始后 1 年至 2 岁时较低,而体重和 BMI-SDS 一直较高,直至 3 岁。在女性中,身高 SDS 在 EoT 及 2 岁时较低,但体重和 BMI-SDS 一直较高,直至 3 岁。在男性中,身高 SDS 在 EoT 和 2 岁时较低;BMI-SDS 的差异在 2 岁时已解决。根据 WHO 标准,3 岁时超重或肥胖的患儿比例高于诊断时(P=0.01)。
儿童 ALL 幸存者,尤其是女性,身高、体重和 BMI-SDS 存在不良变化,这些变化发生在治疗期间,并持续到随访期。在 ALL 治疗和随访期间,应向患者提供适当的饮食和生活方式建议,以减少这些变化并降低相关的长期发病率。